{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:50:11Z","timestamp":1790833811911,"version":"4.1.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Giant Cell Arteritis (GCA) is well known to be a critical ischaemic disease that requires immediate medical recognition to initiate treatment and where one in five people still suffer visual loss. The immunopathophysiology has continued to be characterised, and the influencing of ageing in the development of GCA is beginning to be understood. Recent national and international guidelines have supported the directed use of cranial ultrasound to reduce diagnostic delay and improve clinical outcomes. Immediate high dose glucocorticoids remain the standard emergency treatment for GCA, with a number of targeted agents that have been shown in clinical trials to have superior clinical efficacy and steroid sparing effects. The aim of this review was to present the latest advances in GCA that have the potential to influence routine clinical practice.<\/jats:p>","DOI":"10.1038\/s41433-023-02433-y","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:04:57Z","timestamp":1676383497000},"page":"2365-2373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Giant cell arteritis: reviewing the advancing diagnostics and management"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4293-1981","authenticated-orcid":false,"given":"Edward J.","family":"Bilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6314-4437","authenticated-orcid":false,"given":"Susan P.","family":"Mollan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"2433_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13075-021-02450-w","volume":"23","author":"KJ Li","year":"2021","unstructured":"Li KJ, Semenov D, Turk M, Pope J. A meta-analysis of the epidemiology of giant cell arteritis across time and space. Arthritis Res Ther. 2021;23:82.","journal-title":"Arthritis Res Ther"},{"key":"2433_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/rheumatology\/keu433","volume":"54","author":"SP Mollan","year":"2015","unstructured":"Mollan SP, Begaj I, Mackie S, O\u2019Sullivan EP, Denniston AK. Increase in admissions related to giant cell arteritis and polymyalgia rheumatica in the UK, 2002-13, without a decrease in associated sight loss: potential implications for service provision. Rheumatol (Oxf). 2015;54:375\u20137.","journal-title":"Rheumatol (Oxf)"},{"key":"2433_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3899\/jrheum.140318","volume":"42","author":"E De Smit","year":"2015","unstructured":"De Smit E, Palmer AJ, Hewitt AW. Projected Worldwide Disease Burden from Giant Cell Arteritis by 2050. J Rheumatol. 2015;42:119\u201325.","journal-title":"J Rheumatol"},{"key":"2433_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19\u201330.","journal-title":"Ann Rheum Dis"},{"key":"2433_CR5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/rheumatology\/kez672","volume":"59","author":"SL Mackie","year":"2020","unstructured":"Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology 2020;59:e1\u2013e23.","journal-title":"Rheumatology"},{"key":"2433_CR6","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/art.41774","volume":"73","author":"M Maz","year":"2021","unstructured":"Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. 2021;73:1349\u201365.","journal-title":"Arthritis Rheumatol"},{"key":"2433_CR7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41433-020-1090-y","volume":"35","author":"SP Mollan","year":"2021","unstructured":"Mollan SP, Grech O, O\u2019Sullivan E, Mackie SL. Practice points for ophthalmologists from the 2020 British Society for Rheumatology Giant Cell Arteritis guidelines. Eye 2021;35:699\u2013701.","journal-title":"Eye"},{"key":"2433_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01093-7","volume":"21","author":"SP Mollan","year":"2020","unstructured":"Mollan SP, Paemeleire K, Versijpt J, Luqmani R, Sinclair AJ. European Headache Federation recommendations for neurologists managing giant cell arteritis. J Headache Pain. 2020;21:28.","journal-title":"J Headache Pain"},{"key":"2433_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3109\/03009742.2014.982701","volume":"44","author":"A Chandran","year":"2015","unstructured":"Chandran A, Udayakumar P, Crowson C, Warrington K, Matteson E. The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950\u20132009. Scand J Rheumatol. 2015;44:215\u20138.","journal-title":"Scand J Rheumatol"},{"key":"2433_CR10","doi-asserted-by":"publisher","first-page":"A544","DOI":"10.1016\/j.autrev.2012.01.003","volume":"11","author":"AT Borchers","year":"2012","unstructured":"Borchers AT, Gershwin ME. Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. Autoimmun Rev. 2012;11:A544\u201354.","journal-title":"Autoimmun Rev"},{"key":"2433_CR11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ajhg.2016.11.013","volume":"100","author":"FD Carmona","year":"2017","unstructured":"Carmona FD, Vaglio A, Mackie SL, Hern\u00e1ndez-Rodr\u00edguez J, Monach PA, Casta\u00f1eda S, et al. A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. Am J Hum Genet. 2017;100:64\u201374.","journal-title":"Am J Hum Genet"},{"key":"2433_CR12","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1172\/JCI116125","volume":"90","author":"CM Weyand","year":"1992","unstructured":"Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J Clin Investig. 1992;90:2355\u201361.","journal-title":"J Clin Investig"},{"key":"2433_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/rheumatology\/ket231","volume":"53","author":"FD Carmona","year":"2014","unstructured":"Carmona FD, Gonz\u00e1lez-Gay MA, Mart\u00edn J. Genetic component of giant cell arteritis. Rheumatol (Oxf). 2014;53:6\u201318.","journal-title":"Rheumatol (Oxf)"},{"key":"2433_CR14","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/art.24459","volume":"61","author":"MA Gonzalez-Gay","year":"2009","unstructured":"Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatism. 2009;61:1454\u201361.","journal-title":"Arthritis Rheumatism"},{"key":"2433_CR15","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/jamainternmed.2020.3050","volume":"180","author":"KSM Van Der Geest","year":"2020","unstructured":"Van Der Geest KSM, Sandovici M, Brouwer E, Mackie SL. Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis. JAMA Intern Med. 2020;180:1295.","journal-title":"JAMA Intern Med"},{"key":"2433_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40123-019-0171-0","volume":"8","author":"AZ Al-Mousawi","year":"2019","unstructured":"Al-Mousawi AZ, Gurney SP, Lorenzi AR, Pohl U, Dayan M, Mollan SP. Reviewing the Pathophysiology Behind the Advances in the Management of Giant Cell Arteritis. Ophthalmol Ther. 2019;8:177\u201393.","journal-title":"Ophthalmol Ther"},{"key":"2433_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1084\/jem.20030850","volume":"199","author":"W Ma-Krupa","year":"2004","unstructured":"Ma-Krupa W, Jeon M-S, Spoerl S, Tedder TF, Goronzy JRJ, Weyand CM. Activation of Arterial Wall Dendritic Cells and Breakdown of Self-tolerance in Giant Cell Arteritis. J Exp Med. 2004;199:173\u201383.","journal-title":"J Exp Med"},{"key":"2433_CR18","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.109.872903","volume":"121","author":"J Deng","year":"2010","unstructured":"Deng J, Younge BR, Olshen RA, Goronzy JRJ, Weyand CM. Th17 and Th1 T-Cell Responses in Giant Cell Arteritis. Circulation 2010;121:906\u201315.","journal-title":"Circulation"},{"key":"2433_CR19","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2013.161","volume":"9","author":"CM Weyand","year":"2013","unstructured":"Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol. 2013;9:731\u201340.","journal-title":"Nat Rev Rheumatol"},{"key":"2433_CR20","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nrrheum.2017.142","volume":"13","author":"C Dejaco","year":"2017","unstructured":"Dejaco C, Brouwer E, Mason JC, Buttgereit F, Matteson EL, Dasgupta B. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol. 2017;13:578\u201392.","journal-title":"Nat Rev Rheumatol"},{"key":"2433_CR21","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1136\/ard.2005.039404","volume":"65","author":"K Larsson","year":"2006","unstructured":"Larsson K, Mellstr\u00f6m D, Nordborg C, Od\u00e9n A, Nordberg E. Early menopause, low body mass index, and smoking are independent risk factors for developing giant cell arteritis. Ann Rheum Dis. 2006;65:529\u201332.","journal-title":"Ann Rheum Dis"},{"key":"2433_CR22","first-page":"753","volume":"56","author":"L Li","year":"2017","unstructured":"Li L, Neogi T, Jick S. Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK Clinical Practice Research Datalink. Rheumatol (Oxf). 2017;56:753\u201362.","journal-title":"Rheumatol (Oxf)"},{"key":"2433_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1056\/NEJMcp1214825","volume":"371","author":"CM Weyand","year":"2014","unstructured":"Weyand CM, Goronzy JJ. Giant-Cell Arteritis and Polymyalgia Rheumatica. N Engl J Med. 2014;371:50\u20137.","journal-title":"N Engl J Med"},{"key":"2433_CR24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/WNO.0b013e318268aa9b","volume":"32","author":"CM Weyand","year":"2012","unstructured":"Weyand CM, Liao YJ, Goronzy JJ. The Immunopathology of Giant Cell Arteritis. J Neuro-Ophthalmol. 2012;32:259\u201365.","journal-title":"J Neuro-Ophthalmol"},{"key":"2433_CR25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41569-018-0064-2","volume":"15","author":"L Ferrucci","year":"2018","unstructured":"Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15:505\u201322.","journal-title":"Nat Rev Cardiol"},{"key":"2433_CR26","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41574-018-0059-4","volume":"14","author":"C Franceschi","year":"2018","unstructured":"Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune\u2013metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14:576\u201390.","journal-title":"Nat Rev Endocrinol"},{"key":"2433_CR27","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1161\/CIRCRESAHA.118.311378","volume":"123","author":"Z Ungvari","year":"2018","unstructured":"Ungvari Z, Tarantini S, Donato AJ, Galvan V, Csiszar A. Mechanisms of Vascular Aging. Circ Res. 2018;123:849\u201367.","journal-title":"Circ Res"},{"key":"2433_CR28","doi-asserted-by":"publisher","first-page":"843305","DOI":"10.3389\/fnagi.2022.843305","volume":"14","author":"R Watanabe","year":"2022","unstructured":"Watanabe R, Hashimoto M. Aging-Related Vascular Inflammation: Giant Cell Arteritis and Neurological Disorders. Front Aging Neurosci. 2022;14:843305.","journal-title":"Front Aging Neurosci"},{"key":"2433_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017;377:111\u201321.","journal-title":"N Engl J Med"},{"key":"2433_CR30","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1182\/blood-2004-07-2599","volume":"105","author":"L Ferrucci","year":"2005","unstructured":"Ferrucci L, Corsi A, Lauretani F, Bandinelli S, Bartali B, Taub DD, et al. The origins of age-related proinflammatory state. Blood 2005;105:2294\u20139.","journal-title":"Blood"},{"key":"2433_CR31","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1161\/01.ATV.0000029781.31325.66","volume":"22","author":"EA Bermudez","year":"2002","unstructured":"Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships Among Circulating Interleukin-6, C-Reactive Protein, and Traditional Cardiovascular Risk Factors in Women. Arterioscler Thromb Vasc Biol. 2002;22:1668\u201373.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2433_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41569-020-0431-7","volume":"18","author":"DJ Tyrrell","year":"2021","unstructured":"Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. Nat Rev Cardiol. 2021;18:58\u201368.","journal-title":"Nat Rev Cardiol"},{"key":"2433_CR33","first-page":"1606","volume":"136","author":"S Jaiswal","year":"2020","unstructured":"Jaiswal S. Clonal hematopoiesis and nonhematologic disorders. Blood 2020;136:1606\u201314.","journal-title":"Blood"},{"key":"2433_CR34","doi-asserted-by":"publisher","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","volume":"366","author":"S Jaiswal","year":"2019","unstructured":"Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science 2019;366:eaan4673.","journal-title":"Science"},{"key":"2433_CR35","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/rheumatology\/keab337","volume":"61","author":"M Papo","year":"2022","unstructured":"Papo M, Friedrich C, Delaval L, Boysson H, Viallard JF, Bachmeyer C, et al. Myeloproliferative neoplasms and clonal haematopoiesis in patients with giant cell arteritis: a case-control and exploratory study. Rheumatol (Oxf). 2022;61:775\u201380.","journal-title":"Rheumatol (Oxf)"},{"key":"2433_CR36","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.tig.2019.09.005","volume":"35","author":"L Van Horebeek","year":"2019","unstructured":"Van Horebeek L, Dubois B, Goris A. Somatic Variants: New Kids on the Block in Human Immunogenetics. Trends Genet. 2019;35:935\u201347.","journal-title":"Trends Genet"},{"key":"2433_CR37","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1161\/ATVBAHA.106.137851","volume":"27","author":"J-B Michel","year":"2007","unstructured":"Michel J-B, Thaunat O, Houard X, Meilhac O, Caligiuri G, Nicoletti A. Topological Determinants and Consequences of Adventitial Responses to Arterial Wall Injury. Arterioscler Thromb Vasc Biol. 2007;27:1259\u201368.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2433_CR38","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1161\/01.CIR.0000109140.51366.72","volume":"109","author":"SCG Hollestelle","year":"2004","unstructured":"Hollestelle SCG, De Vries MR, Van Keulen JK, Schoneveld AH, Vink A, Strijder CF, et al. Toll-Like Receptor 4 Is Involved in Outward Arterial Remodeling. Circulation 2004;109:393\u20138.","journal-title":"Circulation"},{"key":"2433_CR39","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1172\/JCI1568","volume":"101","author":"HM Kwon","year":"1998","unstructured":"Kwon HM, Sangiorgi G, Ritman EL, McKenna C, Holmes DR, Schwartz RS, et al. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Investig. 1998;101:1551\u20136.","journal-title":"J Clin Investig"},{"key":"2433_CR40","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/03009742.2018.1506821","volume":"48","author":"G Tomasson","year":"2019","unstructured":"Tomasson G, Bjornsson J, Zhang Y, Gudnason V, Merkel P. Cardiovascular risk factors and incident giant cell arteritis: a population-based cohort study. Scand J Rheumatol. 2019;48:213\u20137.","journal-title":"Scand J Rheumatol"},{"key":"2433_CR41","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1093\/rheumatology\/keaa080","volume":"59","author":"K Wadstr\u00f6m","year":"2020","unstructured":"Wadstr\u00f6m K, Jacobsson L, Mohammad AJ, Warrington KJ, Matteson EL, Turesson C. Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis. Rheumatol (Oxf). 2020;59:3229\u201336.","journal-title":"Rheumatol (Oxf)"},{"key":"2433_CR42","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/WCO.0000000000000889","volume":"34","author":"M Kaushik","year":"2021","unstructured":"Kaushik M, Ponte C, Mollan SP. Current advances in giant cell arteritis. Curr Opin Neurol. 2021;34:133\u201341.","journal-title":"Curr Opin Neurol"},{"key":"2433_CR43","doi-asserted-by":"publisher","first-page":"124","DOI":"10.4997\/JRCPE.2017.203","volume":"47","author":"S Gajree","year":"2017","unstructured":"Gajree S, Borooah S, Dhillon N, Goudie C, Smith C, Aspinall P, et al. Temporal artery biopsies in south-east Scotland: a five year review. J R Coll Physicians Edinb. 2017;47:124\u20138.","journal-title":"J R Coll Physicians Edinb"},{"key":"2433_CR44","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41433-021-01421-4","volume":"35","author":"SP Mollan","year":"2021","unstructured":"Mollan SP, Virdee JS, Bilton EJ, Thaller M, Krishan A, Sinclair AJ. Headache for ophthalmologists: current advances in headache understanding and management. Eye 2021;35:1574\u201386.","journal-title":"Eye"},{"key":"2433_CR45","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/annrheumdis-2017-212649","volume":"77","author":"C Dejaco","year":"2018","unstructured":"Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018;77:636\u201343.","journal-title":"Ann Rheum Dis"},{"key":"2433_CR46","doi-asserted-by":"publisher","unstructured":"Henry IM, Fern\u00e1ndez Fern\u00e1ndez E, Peiteado D, Balsa A, de Miguel E. Diagnostic validity of ultrasound including extra-cranial arteries in giant cell arteritis. Clin Rheumatol. 2022. https:\/\/doi.org\/10.1007\/s10067-022-06420-8.","DOI":"10.1007\/s10067-022-06420-8"},{"key":"2433_CR47","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/01658107.2021.1965627","volume":"46","author":"CM Castillejo Becerra","year":"2022","unstructured":"Castillejo Becerra CM, Crowson CS, Koster MJ, Warrington KJ, Bhatti MT, Chen JJ. Population-based Rate and Patterns of Diplopia in Giant Cell Arteritis. Neuroophthalmology. 2022;46:75\u20139.","journal-title":"Neuroophthalmology"},{"key":"2433_CR48","doi-asserted-by":"crossref","unstructured":"Denniston AK, Murray P. Oxford Handbook of Ophthalmology. 3 ed. Oxford: Oxford University Press; 2014.","DOI":"10.1093\/med\/9780199679980.001.0001"},{"key":"2433_CR49","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/art.21075","volume":"53","author":"C Salvarani","year":"2005","unstructured":"Salvarani C, Cimino L, Macchioni P, Consonni D, Cantini F, Bajocchi G, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum. 2005;53:293\u20137.","journal-title":"Arthritis Rheum"},{"key":"2433_CR50","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0002-9394(99)80192-5","volume":"125","author":"SS Hayreh","year":"1998","unstructured":"Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol. 1998;125:509\u201320.","journal-title":"Am J Ophthalmol"},{"key":"2433_CR51","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/postgradmedj-2019-136623","volume":"95","author":"J Virdee","year":"2019","unstructured":"Virdee J, Horsburgh J, Roque M, Mollan S. A giant escape. Postgrad Med J. 2019;95:346.","journal-title":"Postgrad Med J"},{"key":"2433_CR52","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3899\/jrheum.140188","volume":"42","author":"AG Singh","year":"2015","unstructured":"Singh AG, Kermani TA, Crowson CS, Weyand CM, Matteson EL, Warrington KJ. Visual Manifestations in Giant Cell Arteritis: Trend over 5 Decades in a Population-based Cohort. J Rheumatol. 2015;42:309\u201315.","journal-title":"J Rheumatol"},{"key":"2433_CR53","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/brain\/100.2.209","volume":"100","author":"ME Barricks","year":"1977","unstructured":"Barricks ME, Traviesa DB, Glaser JS, Levy IS. Ophthalmoplegia in cranial arteritis. Brain 1977;100:209\u201321.","journal-title":"Brain"},{"key":"2433_CR54","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/WNO.0b013e31827285cf","volume":"32","author":"SA Bayar","year":"2012","unstructured":"Bayar SA, Gokmen O, Pinarci EY, Altinors DD, Gedik S. Corneal endothelial decompansation and ocular hypotony in a case with temporal arteritis. J Neuroophthalmol. 2012;32:385.","journal-title":"J Neuroophthalmol"},{"key":"2433_CR55","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1016\/j.jcjo.2014.08.015","volume":"49","author":"GM Cavallini","year":"2014","unstructured":"Cavallini GM, Volante V, Bigliardi MC, Mascia MT, Forlini M. Bilateral posterior scleritis as a presenting manifestation of giant cell arteritis: A case report. Can J Ophthalmol. 2014;49:e141\u20133.","journal-title":"Can J Ophthalmol"},{"key":"2433_CR56","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1136\/bjo.87.4.510","volume":"87","author":"R Foroozan","year":"2003","unstructured":"Foroozan R, Buono LM, Savino PJ, Sergott RC. Tonic pupils from giant cell arteritis. Br J Ophthalmol. 2003;87:510\u20132.","journal-title":"Br J Ophthalmol"},{"key":"2433_CR57","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/01.wno.0000249332.95722.22","volume":"26","author":"R Huna-Baron","year":"2006","unstructured":"Huna-Baron R, Mizrachi IB, Glovinsky Y. Intraocular pressure is low in eyes with giant cell arteritis. J Neuroophthalmol. 2006;26:273\u20135.","journal-title":"J Neuroophthalmol"},{"key":"2433_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/209767","volume":"2013","author":"N Kopsachilis","year":"2013","unstructured":"Kopsachilis N, Pefkianaki M, Marinescu A, Sivaprasad S. Giant Cell Arteritis Presenting as Choroidal Infarction. Case Rep Ophthalmol Med. 2013;2013:1\u20133.","journal-title":"Case Rep Ophthalmol Med"},{"key":"2433_CR59","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/112067210901900529","volume":"19","author":"M Papathanassiou","year":"2009","unstructured":"Papathanassiou M, Elezoglu A, Nikita E, Theodossiadis PG, Vergados I. A rare case of peripheral ulcerative keratitis in temporal arteritis. Eur J Ophthalmol. 2009;19:866\u20139.","journal-title":"Eur J Ophthalmol"},{"key":"2433_CR60","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jns.2009.04.027","volume":"284","author":"S Prasad","year":"2009","unstructured":"Prasad S, Baccon J, Galetta SL. Mydriatic pupil in giant cell arteritis. J Neurol Sci. 2009;284:196\u20137.","journal-title":"J Neurol Sci"},{"key":"2433_CR61","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000309105","volume":"182","author":"TM Radda","year":"1981","unstructured":"Radda TM, Bardach H, Riss B. Acute ocular hypotony. A rare complication of temporal arteritis. Ophthalmologica 1981;182:148\u201352.","journal-title":"Ophthalmologica"},{"key":"2433_CR62","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.ophtha.2005.01.036","volume":"112","author":"H Danesh-Meyer","year":"2005","unstructured":"Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 2005;112:1098\u2013103.","journal-title":"Ophthalmology"},{"key":"2433_CR63","doi-asserted-by":"publisher","first-page":"e229236","DOI":"10.1136\/bcr-2019-229236","volume":"12","author":"CR Svasti-Salee","year":"2019","unstructured":"Svasti-Salee CR, Mollan SP, Morgan AW, Quick V. Rapid visual recovery following intravenous tocilizumab in glucocorticoid resistant refractory giant cell arteritis. BMJ Case Rep. 2019;12:e229236.","journal-title":"BMJ Case Rep."},{"key":"2433_CR64","first-page":"506","volume":"56","author":"C Dejaco","year":"2017","unstructured":"Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatol (Oxf). 2017;56:506\u201315.","journal-title":"Rheumatol (Oxf)"},{"key":"2433_CR65","first-page":"57","volume":"37","author":"H de Boysson","year":"2019","unstructured":"de Boysson H, Liozon E, Ly KH, Dumont A, Delmas C, Aouba A. The different clinical patterns of giant cell arteritis. Clin Exp Rheumatol 2019;37:57\u201360.","journal-title":"Clin Exp Rheumatol"},{"key":"2433_CR66","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1365-2796.1990.tb00151.x","volume":"227","author":"GD Desmet","year":"1990","unstructured":"Desmet GD, Knockaert DC, Bobbaers HJ. Temporal arteritis: the silent presentation and delay in diagnosis. J Intern Med. 1990;227:237\u201340.","journal-title":"J Intern Med"},{"key":"2433_CR67","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41433-019-0608-7","volume":"34","author":"HS Lyons","year":"2020","unstructured":"Lyons HS, Quick V, Sinclair AJ, Nagaraju S, Mollan SP. A new era for giant cell arteritis. Eye 2020;34:1013\u201326.","journal-title":"Eye"},{"key":"2433_CR68","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2147\/OPTH.S193460","volume":"ume 13","author":"EB Ing","year":"2019","unstructured":"Ing EB, Miller NR, Nguyen A, Su W, Bursztyn LL, Poole M, et al. Neural network and logistic regression diagnostic prediction models for giant cell arteritis: development and validation. Clin Ophthalmol. 2019;13:421\u201330.","journal-title":"Clin Ophthalmol"},{"key":"2433_CR69","first-page":"104","volume":"37","author":"F Laskou","year":"2019","unstructured":"Laskou F, Coath F, Mackie SL, Banerjee S, Aung T, Dasgupta B. A probability score to aid the diagnosis of suspected giant cell arteritis. Clin Exp Rheumatol. 2019;37:104\u20138.","journal-title":"Clin Exp Rheumatol."},{"key":"2433_CR70","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/art.1780330810","volume":"33","author":"GG Hunder","year":"1990","unstructured":"Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122\u20138.","journal-title":"Arthritis Rheum"},{"key":"2433_CR71","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1136\/ard-2022-223482","volume":"81","author":"PC Grayson","year":"2022","unstructured":"Grayson PC, Ponte C, Suppiah R, Robson JC, Gribbons KB, Judge A, et al. 2022 American College of Rheumatology\/EULAR classification criteria for Takayasu arteritis. Ann Rheum Dis. 2022;81:1654\u201360.","journal-title":"Ann Rheum Dis"},{"key":"2433_CR72","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.ajo.2012.03.045","volume":"154","author":"AP Murchison","year":"2012","unstructured":"Murchison AP, Gilbert ME, Bilyk JR, Eagle RC Jr, Pueyo V, Sergott RC, et al. Validity of the American College of Rheumatology criteria for the diagnosis of giant cell arteritis. Am J Ophthalmol. 2012;154:722\u20139.","journal-title":"Am J Ophthalmol"},{"key":"2433_CR73","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.semarthrit.2011.10.005","volume":"41","author":"TA Kermani","year":"2012","unstructured":"Kermani TA, Schmidt J, Crowson CS, Ytterberg SR, Hunder GG, Matteson EL, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum. 2012;41:866\u201371.","journal-title":"Semin Arthritis Rheum"},{"key":"2433_CR74","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s10067-012-2031-3","volume":"31","author":"A Laria","year":"2012","unstructured":"Laria A, Zoli A, Bocci M, Castri F, Federico F, Ferraccioli GF. Systematic review of the literature and a case report informing biopsy-proven giant cell arteritis (GCA) with normal C-reactive protein. Clin Rheumatol. 2012;31:1389\u201393.","journal-title":"Clin Rheumatol"},{"key":"2433_CR75","first-page":"128","volume":"42","author":"S Zweegman","year":"1993","unstructured":"Zweegman S, Makkink B, Stehouwer CD. Giant-cell arteritis with normal erythrocyte sedimentation rate: case report and review of the literature. Neth J Med. 1993;42:128\u201331.","journal-title":"Neth J Med"},{"key":"2433_CR76","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.ophtha.2010.10.002","volume":"118","author":"MD Walvick","year":"2011","unstructured":"Walvick MD, Walvick MP. Giant cell arteritis: laboratory predictors of a positive temporal artery biopsy. Ophthalmology 2011;118:1201\u20134.","journal-title":"Ophthalmology"},{"key":"2433_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20900","volume":"20","author":"R Luqmani","year":"2016","unstructured":"Luqmani R, Lee E, Singh S, Gillett M, Schmidt WA, Bradburn M, et al. The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess. 2016;20:1\u2013238.","journal-title":"Health Technol Assess"},{"key":"2433_CR78","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/rheumatology\/kez385","volume":"59","author":"E Rubenstein","year":"2020","unstructured":"Rubenstein E, Maldini C, Gonzalez-Chiappe S, Chevret S, Mahr A. Sensitivity of temporal artery biopsy in the diagnosis of giant cell arteritis: a systematic literature review and meta-analysis. Rheumatology 2020;59:1011\u201320.","journal-title":"Rheumatology"},{"key":"2433_CR79","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/jcp.53.2.131","volume":"53","author":"AF Chakrabarty","year":"2000","unstructured":"Chakrabarty AF. AJ Temporal artery biopsy: is there any value in examining biopsies at multiple levels? J Clin Pathol. 2000;53:131\u20136.","journal-title":"J Clin Pathol"},{"key":"2433_CR80","first-page":"504","volume":"51","author":"RG Klein","year":"1976","unstructured":"Klein RG, Campbell RJ, Hunder GG, Carney JA. Skip lesions in temporal arteritis. Mayo Clin Proc. 1976;51:504\u201310.","journal-title":"Mayo Clin Proc"},{"key":"2433_CR81","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/jcp.53.2.137","volume":"53","author":"DN Poller","year":"2000","unstructured":"Poller DN, van Wyk Q, Jeffrey MJ. The importance of skip lesions in temporal arteritis. J Clin Pathol. 2000;53:137\u20139.","journal-title":"J Clin Pathol"},{"key":"2433_CR82","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1001\/jamaophthalmol.2020.6896","volume":"139","author":"DA Cohen","year":"2021","unstructured":"Cohen DA, Chen JJ, Neth BJ, Sabbagh N, Hodge D, Warrington KJ, et al. Discordance Rate Among Bilateral Simultaneous and Sequential Temporal Artery Biopsies in Giant Cell Arteritis: Role of Frozen Sectioning Based on the Mayo Clinic Experience. JAMA Ophthalmol. 2021;139:406\u201313.","journal-title":"JAMA Ophthalmol"},{"key":"2433_CR83","doi-asserted-by":"crossref","unstructured":"Lee AG, Sinclair AJ, Sadaka A, Berry S, Mollan SP. Neuro-Ophthalmology: global trends in diagnosis, treatment and management. Springer; Switzerland; 2019.","DOI":"10.1007\/978-3-319-98455-1"},{"key":"2433_CR84","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/rheumatology\/keu329","volume":"54","author":"F Muratore","year":"2015","unstructured":"Muratore F, Kermani TA, Crowson CS, Green AB, Salvarani C, Matteson EL, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology. 2015;54:463\u201370.","journal-title":"Rheumatology"},{"key":"2433_CR85","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.semarthrit.2020.05.021","volume":"50","author":"E Galli","year":"2020","unstructured":"Galli E, Muratore F, Boiardi L, Restuccia G, Cavazza A, Catanoso M, et al. Significance of inflammation restricted to adventitial\/periadventitial tissue on temporal artery biopsy. Semin Arthritis Rheum. 2020;50:1064\u201372.","journal-title":"Semin Arthritis Rheum"},{"key":"2433_CR86","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1097\/PAS.0000000000000244","volume":"38","author":"A Cavazza","year":"2014","unstructured":"Cavazza A, Muratore F, Boiardi L, Restuccia G, Pipitone N, Pazzola G, et al. Inflamed Temporal Artery: Histologic Findings in 354 Biopsies, With Clinical Correlations. Am J Surg Pathol. 2014;38:1360\u201370.","journal-title":"Am J Surg Pathol"},{"key":"2433_CR87","doi-asserted-by":"publisher","first-page":"e2368","DOI":"10.1097\/MD.0000000000002368","volume":"95","author":"J Hern\u00e1ndez-Rodr\u00edguez","year":"2016","unstructured":"Hern\u00e1ndez-Rodr\u00edguez J, Murgia G, Villar I, Campo E, Mackie SL, Chakrabarty A, et al. Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis. Med (Baltim). 2016;95:e2368.","journal-title":"Med (Baltim)"},{"key":"2433_CR88","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1002\/art.23700","volume":"58","author":"D Chatelain","year":"2008","unstructured":"Chatelain D, Duhaut P, Loire R, Bosshard S, Pellet H, Piette JC, et al. Small-vessel vasculitis surrounding an uninflamed temporal artery: a new diagnostic criterion for polymyalgia rheumatica? Arthritis Rheum. 2008;58:2565\u201373.","journal-title":"Arthritis Rheum"},{"key":"2433_CR89","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1309\/L8HF-VM0Q-F55E-5M83","volume":"115","author":"GM Corcoran","year":"2001","unstructured":"Corcoran GM, Prayson RA, Herzog KM. The significance of perivascular inflammation in the absence of arteritis in temporal artery biopsy specimens. Am J Clin Pathol. 2001;115:342\u20137.","journal-title":"Am J Clin Pathol"},{"key":"2433_CR90","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.humpath.2016.07.004","volume":"57","author":"L Jia","year":"2016","unstructured":"Jia L, Couce M, Barnholtz-Sloan JS, Cohen ML. Is all inflammation within temporal artery biopsies temporal arteritis? Hum Pathol. 2016;57:17\u201321.","journal-title":"Hum Pathol"},{"key":"2433_CR91","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3899\/jrheum.170061","volume":"44","author":"C Le Pendu","year":"2017","unstructured":"Le Pendu C, Meignin V, Gonzalez-Chiappe S, Hij A, Galateau-Sall\u00e9 F, Mahr A. Poor Predictive Value of Isolated Adventitial and Periadventitial Infiltrates in Temporal Artery Biopsies for Diagnosis of Giant Cell Arteritis. J Rheumatol. 2017;44:1039\u201343.","journal-title":"J Rheumatol"},{"key":"2433_CR92","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/art.33362","volume":"64","author":"G Restuccia","year":"2012","unstructured":"Restuccia G, Cavazza A, Boiardi L, Pipitone N, Macchioni P, Bajocchi G, et al. Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: Two subsets of giant cell arteritis. Arthritis Rheumatism. 2012;64:549\u201356.","journal-title":"Arthritis Rheumatism"},{"key":"2433_CR93","doi-asserted-by":"publisher","first-page":"ii22","DOI":"10.1093\/rheumatology\/kex461","volume":"57","author":"WA Schmidt","year":"2018","unstructured":"Schmidt WA. Ultrasound in the diagnosis and management of giant cell arteritis. Rheumatol (Oxf). 2018;57:ii22\u2013ii31.","journal-title":"Rheumatol (Oxf)"},{"key":"2433_CR94","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1055\/s-0032-1312821","volume":"34","author":"M Aschwanden","year":"2012","unstructured":"Aschwanden M, Daikeler T, Kesten F, Baldi T, Benz D, Tyndall A, et al. Temporal Artery Compression Sign - A Novel Ultrasound Finding for the Diagnosis of Giant Cell Arteritis. Ultraschall der Med - Eur J Ultrasound 2012;34:47\u201350.","journal-title":"Ultraschall der Med - Eur J Ultrasound"},{"key":"2433_CR95","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.autrev.2018.07.012","volume":"18","author":"M Rinagel","year":"2019","unstructured":"Rinagel M, Chatelus E, Jousse-Joulin S, Sibilia J, Gottenberg JE, Chasset F, et al. Diagnostic performance of temporal artery ultrasound for the diagnosis of giant cell arteritis: a systematic review and meta-analysis of the literature. Autoimmun Rev. 2019;18:56\u201361.","journal-title":"Autoimmun Rev"},{"key":"2433_CR96","doi-asserted-by":"publisher","first-page":"e001337","DOI":"10.1136\/rmdopen-2020-001337","volume":"6","author":"S Chrysidis","year":"2020","unstructured":"Chrysidis S, Terslev L, Christensen R, Fredberg U, Larsen K, Lorenzen T, et al. Vascular ultrasound for the diagnosis of giant cell arteritis: a reliability and agreement study based on a standardised training programme. RMD Open. 2020;6:e001337.","journal-title":"RMD Open"},{"key":"2433_CR97","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1136\/annrheumdis-2019-216343","volume":"79","author":"KSM Van Der Geest","year":"2020","unstructured":"Van Der Geest KSM, Borg F, Kayani A, Paap D, Gondo P, Schmidt W, et al. Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia. Ann Rheum Dis. 2020;79:393\u20139.","journal-title":"Ann Rheum Dis"},{"key":"2433_CR98","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F","volume":"42","author":"A Brack","year":"1999","unstructured":"Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42:311\u20137.","journal-title":"Arthritis Rheum"},{"key":"2433_CR99","doi-asserted-by":"publisher","first-page":"ii32","DOI":"10.1093\/rheumatology\/kex424","volume":"57","author":"MJ Koster","year":"2018","unstructured":"Koster MJ, Matteson EL, Warrington KJ. Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology 2018;57:ii32\u2013ii42.","journal-title":"Rheumatology"},{"key":"2433_CR100","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1002\/art.11353","volume":"48","author":"DM Nuenninghoff","year":"2003","unstructured":"Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and\/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48:3522\u201331.","journal-title":"Arthritis Rheum"},{"key":"2433_CR101","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/rheumatology\/key383","volume":"58","author":"M Aschwanden","year":"2019","unstructured":"Aschwanden M, Schegk E, Imfeld S, Staub D, Rottenburger C, Berger CT, et al. Vessel wall plasticity in large vessel giant cell arteritis: an ultrasound follow-up study. Rheumatol (Oxf). 2019;58:792\u20137.","journal-title":"Rheumatol (Oxf)"},{"key":"2433_CR102","first-page":"S34","volume":"30","author":"E De Miguel","year":"2012","unstructured":"De Miguel E, Roxo A, Castillo C, Peiteado D, Villalba A, Mart\u00edn-Mola E. The utility and sensitivity of colour Doppler ultrasound in monitoring changes in giant cell arteritis. Clin Exp Rheumatol. 2012;30:S34\u20138.","journal-title":"Clin Exp Rheumatol."},{"key":"2433_CR103","doi-asserted-by":"crossref","unstructured":"Karahaliou M, Vaiopoulos G, Papaspyrou S, Kanakis MA, Revenas K, Sfikakis PP. Arthritis Research & Therapy. 2006;8:R116.","DOI":"10.1186\/ar2003"},{"key":"2433_CR104","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1056\/NEJM199711063371902","volume":"337","author":"WA Schmidt","year":"1997","unstructured":"Schmidt WA, Kraft HE, Vorpahl K, V\u00f6lker L, Gromnica-Ihle EJ. Color Duplex Ultrasonography in the Diagnosis of Temporal Arteritis. N Engl J Med. 1997;337:1336\u201342.","journal-title":"N Engl J Med"},{"key":"2433_CR105","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/modpathol.2017.10","volume":"30","author":"JJ Maleszewski","year":"2017","unstructured":"Maleszewski JJ, Younge BR, Fritzlen JT, Hunder GG, Goronzy JJ, Warrington KJ, et al. Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. Mod Pathol. 2017;30:788\u201396.","journal-title":"Mod Pathol"},{"key":"2433_CR106","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4997\/jrcpe.2015.403","volume":"45","author":"AP Croft","year":"2015","unstructured":"Croft AP, Thompson N, Duddy MJ, Barton C, Khattak F, Mollan SP, et al. Cranial ultrasound for the diagnosis of giant cell arteritis. A retrospective cohort study. J R Coll Physicians Edinb. 2015;45:268\u201372.","journal-title":"J R Coll Physicians Edinb"},{"key":"2433_CR107","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1093\/rheumatology\/keaa475","volume":"59","author":"S Mackie","year":"2020","unstructured":"Mackie S, Neill L, Byrne D, Mollan S, Dasgupta B, Dejaco C. Comment on: British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: reply. Rheumatol (Oxf). 2020;59:e163\u2013e4.","journal-title":"Rheumatol (Oxf)"},{"key":"2433_CR108","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/rheumatology\/kez664","volume":"59","author":"SL Mackie","year":"2020","unstructured":"Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatol (Oxf). 2020;59:487\u201394.","journal-title":"Rheumatol (Oxf)"},{"key":"2433_CR109","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1136\/practneurol-2020-002615","volume":"20","author":"SP Mollan","year":"2020","unstructured":"Mollan SP, Mackie SL. British Society for Rheumatology guideline for diagnosis and treatment of giant cell arteritis. Pr Neurol. 2020;20:474\u20135.","journal-title":"Pr Neurol"},{"key":"2433_CR110","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3390\/jcm11071997","volume":"11","author":"E H\u00e9ron","year":"2022","unstructured":"H\u00e9ron E, Sedira N, Dahia O, Jamart C. Ocular Complications of Giant Cell Arteritis: An Acute Therapeutic Emergency. J Clin Med. 2022;11:1997.","journal-title":"J Clin Med"},{"key":"2433_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0871-z","volume":"15","author":"JA Prior","year":"2017","unstructured":"Prior JA, Ranjbar H, Belcher J, Mackie SL, Helliwell T, Liddle J, et al. Diagnostic delay for giant cell arteritis \u2013 a systematic review and meta-analysis. BMC Med. 2017;15:120.","journal-title":"BMC Med"},{"key":"2433_CR112","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/rheumatology\/kev289","volume":"55","author":"AP Diamantopoulos","year":"2016","unstructured":"Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G. The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatol (Oxf). 2016;55:66\u201370.","journal-title":"Rheumatol (Oxf)"},{"key":"2433_CR113","doi-asserted-by":"publisher","first-page":"589794","DOI":"10.3389\/fmed.2020.589794","volume":"7","author":"S Monti","year":"2020","unstructured":"Monti S, Bartoletti A, Bellis E, Delvino P, Montecucco C. Fast-Track Ultrasound Clinic for the Diagnosis of Giant Cell Arteritis Changes the Prognosis of the Disease but Not the Risk of Future Relapse. Front Med (Lausanne). 2020;7:589794.","journal-title":"Front Med (Lausanne)"},{"key":"2433_CR114","first-page":"S-103-6","volume":"33","author":"P Patil","year":"2015","unstructured":"Patil P, Williams M, Maw WW, Achilleos K, Elsideeg S, Dejaco C, et al. Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol. 2015;33:S-103-6.","journal-title":"Clin Exp Rheumatol."},{"key":"2433_CR115","doi-asserted-by":"publisher","first-page":"e001297","DOI":"10.1136\/rmdopen-2020-001297","volume":"6","author":"A Sebastian","year":"2020","unstructured":"Sebastian A, Tomelleri A, Kayani A, Prieto-Pena D, Ranasinghe C, Dasgupta B. Probability-based algorithm using ultrasound and additional tests for suspected GCA in a fast-track clinic. RMD Open. 2020;6:e001297.","journal-title":"RMD Open"},{"key":"2433_CR116","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1002\/art.22163","volume":"54","author":"M Mazlumzadeh","year":"2006","unstructured":"Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54:3310\u20138.","journal-title":"Arthritis Rheum"},{"key":"2433_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-2-346","volume":"2","author":"DR Seneviratne","year":"2008","unstructured":"Seneviratne DR, Mollan SP, Elsherbiny S, Worstmann T. Giant cell arteritis complicated by acute pancreatitis: a case report. J Med Case Rep. 2008;2:346.","journal-title":"J Med Case Rep."},{"key":"2433_CR118","doi-asserted-by":"publisher","first-page":"rkz001","DOI":"10.1093\/rap\/rkz001","volume":"3","author":"C Mukhtyar","year":"2019","unstructured":"Mukhtyar C, Cate H, Graham C, Merry P, Mills K, Misra A, et al. Development of an evidence-based regimen of prednisolone to treat giant cell arteritis - the Norwich regimen. Rheumatol Adv Pract. 2019;3:rkz001.","journal-title":"Rheumatol Adv Pract."},{"key":"2433_CR119","doi-asserted-by":"publisher","first-page":"e000612","DOI":"10.1136\/rmdopen-2017-000612","volume":"4","author":"C Duftner","year":"2018","unstructured":"Duftner C, Dejaco C, Sepriano A, Falzon L, Schmidt WA, Ramiro S. Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations. RMD Open. 2018;4:e000612.","journal-title":"RMD Open"},{"key":"2433_CR120","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/rheumatology\/kex397","volume":"57","author":"TA Kermani","year":"2018","unstructured":"Kermani TA, Sreih AG, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, et al. Evaluation of damage in giant cell arteritis. Rheumatol (Oxf). 2018;57:322\u20138.","journal-title":"Rheumatol (Oxf)"},{"key":"2433_CR121","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.semarthrit.2016.10.001","volume":"46","author":"JC Wilson","year":"2017","unstructured":"Wilson JC, Sarsour K, Collinson N, Tuckwell K, Musselman D, Klearman M, et al. Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis. Semin Arthritis Rheum. 2017;46:650\u20136.","journal-title":"Semin Arthritis Rheum"},{"key":"2433_CR122","doi-asserted-by":"publisher","first-page":"381","DOI":"10.7861\/clinmedicine.10-4-381","volume":"10","author":"B Dasgupta","year":"2010","unstructured":"Dasgupta B. Concise guidance: diagnosis and management of giant cell arteritis. Clin Med (Lond). 2010;10:381\u20136.","journal-title":"Clin Med (Lond)"},{"key":"2433_CR123","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/acr.22429","volume":"67","author":"H Petri","year":"2015","unstructured":"Petri H, Nevitt A, Sarsour K, Napalkov P, Collinson N. Incidence of giant cell arteritis and characteristics of patients: data-driven analysis of comorbidities. Arthritis Care Res (Hoboken). 2015;67:390\u20135.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2433_CR124","doi-asserted-by":"publisher","first-page":"107","DOI":"10.7861\/clinmed.2022-0041","volume":"22","author":"R Piccus","year":"2022","unstructured":"Piccus R, Hansen MS, Hamann S, Mollan SP. An update on the clinical approach to giant cell arteritis. Clin Med (Lond). 2022;22:107\u201311.","journal-title":"Clin Med (Lond)"},{"key":"2433_CR125","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1002\/art.22754","volume":"56","author":"AD Mahr","year":"2007","unstructured":"Mahr AD, Jover JA, Spiera RF, Hern\u00e1ndez-Garc\u00eda C, Fern\u00e1ndez-Guti\u00e9rrez B, Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56:2789\u201397.","journal-title":"Arthritis Rheum"},{"key":"2433_CR126","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10067-018-4232-x","volume":"38","author":"A Ho\u010devar","year":"2019","unstructured":"Ho\u010devar A, Je\u0161e R, Rotar \u017d, Tom\u0161i\u010d M. Does leflunomide have a role in giant cell arteritis? An open-label study. Clin Rheumatol. 2019;38:291\u20136.","journal-title":"Clin Rheumatol"},{"key":"2433_CR127","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/j.1742-1241.2012.02981.x","volume":"66","author":"T Adizie","year":"2012","unstructured":"Adizie T, Christidis D, Dharmapaliah C, Borg F, Dasgupta B. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. Int J Clin Pr. 2012;66:906\u20139.","journal-title":"Int J Clin Pr"},{"key":"2433_CR128","doi-asserted-by":"publisher","first-page":"120638","DOI":"10.1155\/2013\/120638","volume":"2013","author":"AP Diamantopoulos","year":"2013","unstructured":"Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int. 2013;2013:120638.","journal-title":"Biomed Res Int"},{"key":"2433_CR129","doi-asserted-by":"publisher","first-page":"1069013","DOI":"10.3389\/fmed.2022.1069013","volume":"9","author":"J Kramari\u010d","year":"2022","unstructured":"Kramari\u010d J, Rotar \u017d, Tom\u0161i\u010d M, Ho\u010devar A. Performance of leflunomide as a steroid-sparing agent in giant cell arteritis: A single-center, open-label study. Front Med (Lausanne). 2022;9:1069013.","journal-title":"Front Med (Lausanne)"},{"key":"2433_CR130","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/03009742.2019.1575980","volume":"48","author":"S Tengesdal","year":"2019","unstructured":"Tengesdal S, Diamantopoulos AP, Myklebust G. Leflunomide versus methotrexate in treatment of giant cell arteritis: comparison of efficacy, safety, and drug survival. Scand J Rheumatol. 2019;48:333\u20135.","journal-title":"Scand J Rheumatol"},{"key":"2433_CR131","first-page":"Cd010453","volume":"3","author":"SP Mollan","year":"2014","unstructured":"Mollan SP, Sharrack N, Burdon MA, Denniston AK. Aspirin as adjunctive treatment for giant cell arteritis. Cochrane Database Syst Rev. 2014;3:Cd010453.","journal-title":"Cochrane Database Syst Rev"},{"key":"2433_CR132","first-page":"Cd013484","volume":"8","author":"AA Antonio","year":"2021","unstructured":"Antonio AA, Santos RN, Abariga SA. Tocilizumab for giant cell arteritis. Cochrane Database Syst Rev. 2021;8:Cd013484.","journal-title":"Cochrane Database Syst Rev"},{"key":"2433_CR133","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377:317\u201328.","journal-title":"N Engl J Med"},{"key":"2433_CR134","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","volume":"387","author":"PM Villiger","year":"2016","unstructured":"Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016;387:1921\u20137.","journal-title":"Lancet"},{"key":"2433_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/EB.S127812","volume":"10","author":"SP Mollan","year":"2018","unstructured":"Mollan SP, Horsburgh J, Dasgupta B. Profile of tocilizumab and its potential in the treatment of giant cell arteritis. Eye Brain. 2018;10:1\u201311.","journal-title":"Eye Brain"},{"key":"2433_CR136","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S2665-9913(21)00038-2","volume":"3","author":"JH Stone","year":"2021","unstructured":"Stone JH, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. Lancet Rheumatol. 2021;3:e328\u2013e36.","journal-title":"Lancet Rheumatol."},{"key":"2433_CR137","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1093\/rheumatology\/keab780","volume":"61","author":"JH Stone","year":"2022","unstructured":"Stone JH, Spotswood H, Unizony SH, Aringer M, Blockmans D, Brouwer E, et al. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Rheumatol (Oxf). 2022;61:2915\u201322.","journal-title":"Rheumatol (Oxf)"},{"key":"2433_CR138","unstructured":"NICE. Tocilizumab for treating giant cell arteritis: technology appraisal guidance [TA518]: National Institute for Health and Care Excellence; 2018; [cited 2022 30th December]. https:\/\/www.nice.org.uk\/guidance\/ta518\/chapter\/1-Recommendations."},{"key":"2433_CR139","unstructured":"SMC. Tocilizumab, 162 mg solution for injection in pre-filled syringe and pre-filled pen (RoActemra\u00ae). Scottish Medicines Consortium; 2018; [cited 2022 30th December]. https:\/\/www.scottishmedicines.org.uk\/media\/3693\/tocilizumab-roactemra-final-august-2018-for-website.pdf."},{"key":"2433_CR140","doi-asserted-by":"publisher","first-page":"rkac017","DOI":"10.1093\/rap\/rkac017","volume":"6","author":"O Cronin","year":"2022","unstructured":"Cronin O, Preston H, Fahmy H, Kuske B, Singh M, Scott N, et al. Tocilizumab for the treatment of giant cell arteritis in Scotland: a report on behalf of the Scottish Society for Rheumatology standards subgroup. Rheumatol Adv Pract. 2022;6:rkac017.","journal-title":"Rheumatol Adv Pract."},{"key":"2433_CR141","doi-asserted-by":"publisher","first-page":"rkac037","DOI":"10.1093\/rap\/rkac037","volume":"6","author":"R Conway","year":"2022","unstructured":"Conway R, Putman MS, Mackie SL. Benchmarking tocilizumab use for giant cell arteritis. Rheumatol Adv Pract. 2022;6:rkac037.","journal-title":"Rheumatol Adv Pract."},{"key":"2433_CR142","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/S2665-9913(20)30386-6","volume":"3","author":"SL Mackie","year":"2021","unstructured":"Mackie SL, Brouwer E, Conway R, van der Geest KSM, Mehta P, Mollan SP, et al. Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. Lancet Rheumatol. 2021;3:e71\u2013e82.","journal-title":"Lancet Rheumatol"},{"key":"2433_CR143","doi-asserted-by":"crossref","unstructured":"Nguyen AAK, Sammel AM, Mollan SP, Subramanian PS, Fraser CL. Giant Cell Arteritis Incidence During the COVID Pandemic. J Neuroophthalmol. 2022.","DOI":"10.1097\/WNO.0000000000001638"},{"key":"2433_CR144","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0161-6420(02)01775-X","volume":"110","author":"R Foroozan","year":"2003","unstructured":"Foroozan R, Deramo VA, Buono LM, Jayamanne DG, Sergott RC, Danesh-Meyer H, et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology 2003;110:539\u201342.","journal-title":"Ophthalmology"},{"key":"2433_CR145","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0161-6420(97)30222-X","volume":"104","author":"WT Cornblath","year":"1997","unstructured":"Cornblath WT, Eggenberger ER. Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone. Ophthalmology 1997;104:854\u20138.","journal-title":"Ophthalmology"},{"key":"2433_CR146","first-page":"734","volume":"40","author":"MF Curumthaullee","year":"2022","unstructured":"Curumthaullee MF, Liozon E, Dumonteil S, Gondran G, Fauchais AL, Ly KH, et al. Features and risk factors for new (secondary) permanent visual involvement in giant cell arteritis. Clin Exp Rheumatol. 2022;40:734\u201340.","journal-title":"Clin Exp Rheumatol"},{"key":"2433_CR147","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13075-020-02377-8","volume":"23","author":"S Unizony","year":"2021","unstructured":"Unizony S, McCulley TJ, Spiera R, Pei J, Sidiropoulos PN, Best JH, et al. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations. Arthritis Res Ther. 2021;23:8.","journal-title":"Arthritis Res Ther"},{"key":"2433_CR148","doi-asserted-by":"crossref","unstructured":"Dejaco C, Kerschbaumer A, Aletaha D, Bond M, Hysa E, Camellino D, et al. Treat-to-target Recommendations in Giant Cell Arteritis and Polymyalgia Rheumatica. Ann Rheumatic Dis. 2023, in press.","DOI":"10.1136\/ard-2022-223429"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02433-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02433-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02433-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T15:08:22Z","timestamp":1690988902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02433-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":148,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2433"],"URL":"https:\/\/doi.org\/10.1038\/s41433-023-02433-y","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"assertion":[{"value":"31 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr EJB has no competing interests to declare. Professor SPM reports consultancy fees (Invex Therapeutics); advisory board fees (Invex therapeutics; Gensight) and speaker fees (Heidelberg engineering; Chugai-Roche Ltd; Allergan; Santen; Chiesi; and Santhera).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}